Nothing Special   »   [go: up one dir, main page]

NZ501427A - Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant - Google Patents

Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant

Info

Publication number
NZ501427A
NZ501427A NZ501427A NZ50142798A NZ501427A NZ 501427 A NZ501427 A NZ 501427A NZ 501427 A NZ501427 A NZ 501427A NZ 50142798 A NZ50142798 A NZ 50142798A NZ 501427 A NZ501427 A NZ 501427A
Authority
NZ
New Zealand
Prior art keywords
helicobacter pylori
polypeptide
flagella
mucosal adjuvant
vaccine compositions
Prior art date
Application number
NZ501427A
Inventor
Thomas Berglindh
Bjorn Mellgar
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NZ501427A publication Critical patent/NZ501427A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The vaccine composition comprises a Helicobacter pylori FlgE polypeptide, or a modified form thereof retaining functionally equivalent antigenicity and a mucosal adjuvant for use in inducing a protective immune response to Helicobacter pylori infection in mammal. A Helicobacter pylori FlgE polypeptide, or a modified form thereof retaining functionally equivalent antigenicity is used in the manufacture of a medicament for the treatment, prophylaxis or diagnosis of Helicobacter pylori infection in mammal.
NZ501427A 1997-06-12 1998-06-08 Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant NZ501427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702242A SE9702242D0 (en) 1997-06-12 1997-06-12 Vaccine compositions V
PCT/SE1998/001093 WO1998056816A1 (en) 1997-06-12 1998-06-08 VACCINE COMPOSITIONS COMPRISING THE HELICOBACTER PYLORI FlgE POLYPEPTIDE

Publications (1)

Publication Number Publication Date
NZ501427A true NZ501427A (en) 2000-09-29

Family

ID=20407351

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ501427A NZ501427A (en) 1997-06-12 1998-06-08 Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant

Country Status (21)

Country Link
EP (1) EP1009764A1 (en)
JP (1) JP2002507118A (en)
KR (1) KR20010013699A (en)
CN (1) CN1259960A (en)
AR (1) AR012896A1 (en)
AU (1) AU8048798A (en)
BR (1) BR9810026A (en)
CA (1) CA2293293A1 (en)
EE (1) EE9900566A (en)
HU (1) HUP0003164A3 (en)
ID (1) ID23052A (en)
IL (1) IL133144A0 (en)
IS (1) IS5288A (en)
NO (1) NO996132L (en)
NZ (1) NZ501427A (en)
PL (1) PL337503A1 (en)
SE (1) SE9702242D0 (en)
SK (1) SK173099A3 (en)
TR (1) TR199903060T2 (en)
WO (1) WO1998056816A1 (en)
ZA (1) ZA984696B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784687A (en) * 2015-04-27 2015-07-22 苏州大学附属第一医院 Application of flagellar hook protein FlgE of reorganized pseudomonas aeruginosa
CN113425717B (en) * 2021-04-22 2023-06-16 成都欧林生物科技股份有限公司 Medicament for improving efficacy of oral helicobacter pylori vaccine and application thereof
CN116535472B (en) * 2023-05-31 2024-04-30 四川大学华西医院 Helicobacter pylori recombinant protein antigen FlgK and preparation method and application thereof
CN118105473B (en) * 2024-04-30 2024-08-16 成都欧林生物科技股份有限公司 Oral immunogenic composition for preventing or treating Hp infection and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
AR003125A1 (en) * 1995-06-01 1998-07-08 Astra Ab BACTERIAL ANTIGENS FOR THE DIAGNOSIS OF INFECTIONS WITH HELICOBACTER PYLORI, A DNA MOLECLE THAT CODES IT, A VECTOR, A HOST CELL, A PROCEDURE FOR PRODUCING THE POLIPEPTIDE, USE OF ELEPIPETICO, AND PROAPILY USE

Also Published As

Publication number Publication date
NO996132L (en) 2000-01-28
BR9810026A (en) 2000-09-19
JP2002507118A (en) 2002-03-05
NO996132D0 (en) 1999-12-10
WO1998056816A1 (en) 1998-12-17
EP1009764A1 (en) 2000-06-21
AU8048798A (en) 1998-12-30
PL337503A1 (en) 2000-08-28
CA2293293A1 (en) 1998-12-17
IS5288A (en) 1999-12-08
CN1259960A (en) 2000-07-12
ID23052A (en) 2000-01-20
HUP0003164A2 (en) 2000-12-28
ZA984696B (en) 1999-01-04
HUP0003164A3 (en) 2001-10-29
TR199903060T2 (en) 2000-09-21
EE9900566A (en) 2000-06-15
SE9702242D0 (en) 1997-06-12
SK173099A3 (en) 2000-06-12
AR012896A1 (en) 2000-11-22
KR20010013699A (en) 2001-02-26
IL133144A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ES2176232T3 (en) ADEQUATE VACCINE TO BE USED IN THE PREVENTION AND TREATMENT OF INFECTION WITH HELICOBACTER.
IL140217A0 (en) Particles of hcv envelope proteins: use for vaccination
ZA956412B (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
ES8704350A1 (en) Conjugate constituted by a proteic surface adhesive of Streptococcus mutans, and by a polysaccharide of Streptococcus mutans, its preparation and its use, particularly in anti-caries vaccines.
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
GB2303854B (en) Helicobacter proteins and vaccines
GB9419979D0 (en) Vaccine compositions
HUP9801266A2 (en) Multimeric, recombinant urease vaccine
WO2002100340A3 (en) Improved vaccination against anthrax
HUP9801223A2 (en) Method for enhancing the antibody response to specific antigens with interleukin-10
DE69828801D1 (en) PEPTIDE DERIVED FROM THE BINDING (G) PROTEIN OF THE RESPIRATORY SYNZYTIALVIRUS
NZ501427A (en) Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant
HK1138516A1 (en) Parenteral vaccine formulations and uses thereof
ZA919907B (en) Use of il-4 to enhance immune response to immunogens in vaccines
AR010568A1 (en) POLYPEPTIDE, VACCINE COMPOSITION, USE OF POLYPEPTIDE IN THE MANUFACTURE OF A COMPOSITION, AND METHOD TO PRODUCE AN IMMUNO-PROTECTIVE RESPONSE AGAINST HELICOBACTER PYLORI INFECTION
HK1025220A1 (en) Novel saponin compositions and uses thereof
IL97600A0 (en) Use of il-4 to enhance immune response to infectious antigenic challenges
CA2516661A1 (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
NO995290L (en) Anti-helicobacter vaccine composition for use of the subdiafragmatic systemic route and combined mucosal / parenteral immunization method
SE9702240D0 (en) Vaccine compositions III
RU98123839A (en) HELICOBACTER PYLORI VACCINE COMPOSITION CONTAINING FLAGELLIN POLYPEPTIDE
Lindberg et al. Cell-mediated immune reactivity against Salmonella antigens in enteric infection.
Reznik et al. A modern status of tick borrelioses foci in the south of the Turkmen SSR.
TH34526A (en) Bacterial antigens and component II of vaccines.